Dr. Edwin M. Posadas is the Medical Director of Urologic Oncology Program and Clinical Chief of the Division of Hematology/Oncology and holds the rank of Associate Professor of Medicine at Cedars-Sinai Medical Center. He also holds the rank of Associate Professor of Medicine at the David Geffen School of Medicine at University of California, Los Angeles. Dr. Posadas earned his undergraduate and medical degrees at Johns Hopkins University and served his residency at the University of Michigan Medical Center. Dr. Posadas has more than 15 years of experience in clinical oncology and translational research with interests in the treatment of advanced prostate cancer (PCa) and the biology of cancer metastasis, the mechanisms through which cancer cells in localized tumors spread to other parts of the body. These works involve defining the function of the FYN kinase- a molecular target identified by his laboratory- in metastatic progression in castration-resistant PCa (CRPC). Complementary to this, his laboratory is also exploring the nature of circulating tumor cells (CTCs), the rare tumor cells shed from tumors into the blood stream mediating metastasis in cancer. Over the past five years, Dr. Posadas has initiated a variety of IRB-approved protocols for biospecimen collection, including a joint operation with the Cedars-Sinai BioBank and other institutes, which have provided samples for multiple translational studies. Recently through a partnership with CytoLumina, Dr. Posadas and his team identified a subpopulation of CTCs named very-small-nuclear CTCs (vsnCTCs) defined by nuclear size criteria, and demonstrated a strong correlation with lethal progression event to visceral organs in prostate cancer patients.